Braveheart Bio, Inc. - 10-Q Filing
Braveheart Bio, Inc. reports Q3 2026 financial results with 89.87 million common shares outstanding as of November 6, 2026.
Tickers: $BRVE
Braveheart Bio, Inc. reports Q3 2026 financial results with 89.87 million common shares outstanding as of November 6, 2026.
Tickers: $BRVE